UNSPSC 51281520: Para-aminosalicylate sodium

Aminosalicylate sodium belongs to the family of medicines called anti-infectives. It is used with other medicines, to help the body overcome tuberculosis (TB). It will not work for colds, flu, or other virus infections.

UNSPSC 51281520 Para-aminosalicylate sodium is a Commodity code that captures pharmaceutical products and related delivery systems procured by state and local government health and wellness programs. Recent state and local opportunities tagged under this code show demand for naloxone and drug deactivation systems, generic multi-source pharmaceuticals, and prescription fulfillment infrastructure rather than the specific drug compound the code nominally describes. State and local issuing bodies soliciting under this code include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Vendors typically supply through authorized wholesaler networks, must maintain cGMP and Drug Supply Chain Security Act compliance, and are required to hold insurance coverage including commercial general liability of $2,000,000 to $5,000,000 and workers' compensation. Contracts generally run two years with optional renewal periods.

Recent activity spans Florida, Texas, and the upper Midwest. Seminole County, Florida issued IFB 60459723LAS in June 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford; the bid closed July 26, 2023, with a two-year initial term and one-year renewal option. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program addressing direct contracting between state pharmacy benefit programs and manufacturers outside traditional pharmacy benefit manager and wholesaler arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products; the deadline was March 26, 2026, with contract awards effective July 1, 2026, and vendor participation required through authorized wholesalers including AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC, subject to a 3 percent administrative fee and performance penalties ranging from $200 to $1,500 per violation.